We've merged Palleos Healthcare to form a wide-reaching European CRO.
Find out more
This episode of Industry Voice highlights a major area of any drug research process. Biostatistics is involved in every step of clinical research including trial design, protocol development, data management and clinical trial reporting. This time our guest is Kristina Bondareva, Head of Biostatistics at OCT Clinical. She will share her thoughts on the role of biostatistics in general, and also comment on the EMA adoption of the E9(R1) addendum on estimands and sensitivity analysis.
To learn more on the topic watch a webinar on the ICH E9(R1) Addendum on Estimands and Sensitivity Analysis.
 Addendum on Estimands and Sensitivity Analysis&p%5Bsummary%5D=DESC&p%5Burl%5D=https://oct-clinicaltrials.com/kr/resources/oct-tv/industry-voice-14-ich-e9-r1-addendum-on-estimands-and-sensitivity-analysis&p%5Bimages%5D%5B0%5D=https://oct-clinicaltrials.com/kr/assets/images/1365/1365-j9bgfx-IV_14_News_Cover.jpg)
OCT Clinical is now operating under Palleos Healthcare brand name.
“The merger will undoubtedly create significant synergies, not just doubling but squaring the expertise of both companies”, Philip Räth, Ph.D., managing director at Palleos, said in the release.
“OCT Clinical is proud to join forces with palleos healthcare, as it has an excellent reputation in the industry it serves. Now we can offer tailored solutions to our clients to meet their diverse clinical research needs and accelerate the time of bringing their products to market”, Dmitry Sharov, CEO at OCT Clinical.
